On Oct. 11, 2021, Inovio Pharmaceuticals announced that it had received authorization from Colombia’s INVIMA, to conduct the Phase 3 segment of INOVIO’s global Phase 2/3 trial, INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy) in Colombia, for INO-4800, its DNA vaccine candidate for COVID-19.

INOVIO was working with partner Advaccine Biopharmaceuticals Suzhou on the INNOVATE Phase 3 segment in multiple countries, with a focus on countries in Latin America, Asia, and Africa. INOVIO earlier received regulatory authorization to proceed in Brazil, Philippines, and Mexico.